Enantioselective synthesis

Enantioselective synthesis, also called asymmetric synthesis,^[1] is a form of chemical synthesis. It is defined by IUPAC as "a chemical reaction (or reaction sequence) in which one or more new elements of chirality are formed in a substrate molecule and which produces the stereoisomeric (enantiomeric or diastereomeric) products in unequal amounts."^[2]

In the Sharpless dihydroxylation reaction the chirality of the product can be controlled by the "AD-mix" used. This is an example of enantioselective synthesis using asymmetric induction

Key: R_L = Largest substituent; R_M = Medium-sized substituent; R_S = Smallest substituent

Two enantiomers of a generic alpha amino acid

  Carbon at the chiral center

  Carboxylic acid group

  R group

  Hydrogen

Put more simply: it is the synthesis of a compound by a method that favors the formation of a specific enantiomer or diastereomer. Enantiomers are stereoisomers that have opposite configurations at every chiral center. Diastereomers are stereoisomers that differ at one or more chiral centers.

Enantioselective synthesis is a key process in modern chemistry and is particularly important in the field of pharmaceuticals, as the different enantiomers or diastereomers of a molecule often have different biological activity.

Overview

 

An energy profile of an enantioselective addition reaction.

Many of the building blocks of biological systems such as sugars and amino acids are produced exclusively as one enantiomer. As a result, living systems possess a high degree of chemical chirality and will often react differently with the various enantiomers of a given compound. Examples of this selectivity include:

• Flavour: the artificial sweetener aspartame has two enantiomers. L-aspartame tastes sweet whereas D-aspartame is tasteless.^[3]
• Odor: R-(–)-carvone smells like spearmint whereas S-(+)-carvone smells like caraway.^[4]
• Drug effectiveness: the antidepressant drug Citalopram is sold as a racemic mixture. However, studies have shown that only the (S)-(+) enantiomer is responsible for the drug's beneficial effects.^[5][6]
• Drug safety: D‑penicillamine is used in chelation therapy and for the treatment of rheumatoid arthritis whereas L‑penicillamine is toxic as it inhibits the action of pyridoxine, an essential B vitamin.^[7][8]

As such enantioselective synthesis is of great importance but it can also be difficult to achieve. Enantiomers possess identical enthalpies and entropies and hence should be produced in equal amounts by an undirected process – leading to a racemic mixture. Enantioselective synthesis can be achieved by using a chiral feature that favors the formation of one enantiomer over another through interactions at the transition state. This biasing is known as asymmetric induction and can involve chiral features in the substrate, reagent, catalyst, or environment^[9] and works by making the activation energy required to form one enantiomer lower than that of the opposing enantiomer.^[10]

Enantioselectivity is usually determined by the relative rates of an enantiodifferentiating step—the point at which one reactant can become either of two enantiomeric products. The rate constant, k, for a reaction is function of the activation energy of the reaction, sometimes called the energy barrier, and is temperature-dependent. Using the Gibbs free energy of the energy barrier, ΔG*, means that the relative rates for opposing stereochemical outcomes at a given temperature, T, is:

${\displaystyle {\frac {k_{1}}{k_{2}}}=10^{\frac {\Delta \Delta G^{*}}{T\times 1.98\times 2.3}}}$ 

This temperature dependence means the rate difference, and therefore the enantioselectivity, is greater at lower temperatures. As a result, even small energy-barrier differences can lead to a noticeable effect.

ΔΔG* (kcal)	k1/k2 at 273 K		k1/k2 at 298 K		k1/k2 at 323 K)
1.0	6	.37	5	.46	4	.78
2.0	40	.6	29	.8	22	.9
3.0	259		162		109
4.0	1650		886		524
5.0	10500		4830		2510

Approaches

Enantioselective catalysis

Enantioselective catalysis (known traditionally as "asymmetric catalysis") is performed using chiral catalysts, which are typically chiral coordination complexes. Catalysis is effective for a broader range of transformations than any other method of enantioselective synthesis. The chiral metal catalysts are almost invariably rendered chiral by using chiral ligands, but it is possible to generate chiral-at-metal complexes composed entirely of achiral ligands.^[11][12][13] Most enantioselective catalysts are effective at low substrate/catalyst ratios.^[14][15] Given their high efficiencies, they are often suitable for industrial scale synthesis, even with expensive catalysts.^[16] A versatile example of enantioselective synthesis is asymmetric hydrogenation, which is used to reduce a wide variety of functional groups.

 

The design of new catalysts is dominated by the development of new classes of ligands. Certain ligands, often referred to as "privileged ligands", are effective in a wide range of reactions; examples include BINOL, Salen, and BOX. Most catalysts are effective for only one type of asymmetric reaction. For example, Noyori asymmetric hydrogenation with BINAP/Ru requires a β-ketone, although another catalyst, BINAP/diamine-Ru, widens the scope to α,β-alkenes and aromatic chemicals.

Chiral auxiliaries

Main article: Chiral auxiliary

A chiral auxiliary is an organic compound which couples to the starting material to form a new compound which can then undergo diastereoselective reactions via intramolecular asymmetric induction.^[17][18] At the end of the reaction the auxiliary is removed, under conditions that will not cause racemization of the product.^[19] It is typically then recovered for future use.

 

Chiral auxiliaries must be used in stoichiometric amounts to be effective and require additional synthetic steps to append and remove the auxiliary. However, in some cases the only available stereoselective methodology relies on chiral auxiliaries and these reactions tend to be versatile and very well-studied, allowing the most time-efficient access to enantiomerically pure products.^[18] Additionally, the products of auxiliary-directed reactions are diastereomers, which enables their facile separation by methods such as column chromatography or crystallization.

Biocatalysis

Main article: Biocatalysis

Biocatalysis makes use of biological compounds, ranging from isolated enzymes to living cells, to perform chemical transformations.^[20][21] The advantages of these reagents include very high e.e.s and reagent specificity, as well as mild operating conditions and low environmental impact. Biocatalysts are more commonly used in industry than in academic research;^[22] for example in the production of statins.^[23] The high reagent specificity can be a problem, however, as it often requires that a wide range of biocatalysts be screened before an effective reagent is found.

Enantioselective organocatalysis

Main article: Organocatalysis

Organocatalysis refers to a form of catalysis, where the rate of a chemical reaction is increased by an organic compound consisting of carbon, hydrogen, sulfur and other non-metal elements.^[24][25] When the organocatalyst is chiral, then enantioselective synthesis can be achieved;^[26][27] for example a number of carbon–carbon bond forming reactions become enantioselective in the presence of proline with the aldol reaction being a prime example.^[28] Organocatalysis often employs natural compounds and secondary amines as chiral catalysts;^[29] these are inexpensive and environmentally friendly, as no metals are involved.

Chiral pool synthesis

Main article: Chiral pool synthesis

Chiral pool synthesis is one of the simplest and oldest approaches for enantioselective synthesis. A readily available chiral starting material is manipulated through successive reactions, often using achiral reagents, to obtain the desired target molecule. This can meet the criteria for enantioselective synthesis when a new chiral species is created, such as in an S_N2 reaction.

 

Chiral pool synthesis is especially attractive for target molecules having similar chirality to a relatively inexpensive naturally occurring building-block such as a sugar or amino acid. However, the number of possible reactions the molecule can undergo is restricted and tortuous synthetic routes may be required (e.g. Oseltamivir total synthesis). This approach also requires a stoichiometric amount of the enantiopure starting material, which can be expensive if it is not naturally occurring.

Separation and analysis of enantiomers

The two enantiomers of a molecule possess many of the same physical properties (e.g. melting point, boiling point, polarity etc.) and so behave identically to each other. As a result, they will migrate with an identical R_f in thin layer chromatography and have identical retention times in HPLC and GC. Their NMR and IR spectra are identical.

This can make it very difficult to determine whether a process has produced a single enantiomer (and crucially which enantiomer it is) as well as making it hard to separate enantiomers from a reaction which has not been 100% enantioselective. Fortunately, enantiomers behave differently in the presence of other chiral materials and this can be exploited to allow their separation and analysis.

Enantiomers do not migrate identically on chiral chromatographic media, such as quartz or standard media that has been chirally modified. This forms the basis of chiral column chromatography, which can be used on a small scale to allow analysis via GC and HPLC, or on a large scale to separate chirally impure materials. However this process can require large amount of chiral packing material which can be expensive. A common alternative is to use a chiral derivatizing agent to convert the enantiomers into a diastereomers, in much the same way as chiral auxiliaries. These have different physical properties and hence can be separated and analysed using conventional methods. Special chiral derivitizing agents known as 'chiral resolution agents' are used in the NMR spectroscopy of stereoisomers, these typically involve coordination to chiral europium complexes such as Eu(fod)₃ and Eu(hfc)₃.

The separation and analysis of component enantiomers of a racemic drugs or pharmaceutical substances are referred to as chiral analysis.^[30] or enantioselective analysis. The most frequently employed technique to carry out chiral analysis involves separation science procedures, specifically chiral chromatographic methods.^[31]

The enantiomeric excess of a substance can also be determined using certain optical methods. The oldest method for doing this is to use a polarimeter to compare the level of optical rotation in the product against a 'standard' of known composition. It is also possible to perform ultraviolet-visible spectroscopy of stereoisomers by exploiting the Cotton effect.

One of the most accurate ways of determining the chirality of compound is to determine its absolute configuration by X-ray crystallography. However this is a labour-intensive process which requires that a suitable single crystal be grown.

History

Inception (1815–1905)

In 1815 the French physicist Jean-Baptiste Biot showed that certain chemicals could rotate the plane of a beam of polarised light, a property called optical activity.^[32] The nature of this property remained a mystery until 1848, when Louis Pasteur proposed that it had a molecular basis originating from some form of dissymmetry,^[33][34] with the term chirality being coined by Lord Kelvin a year later.^[35] The origin of chirality itself was finally described in 1874, when Jacobus Henricus van 't Hoff and Joseph Le Bel independently proposed the tetrahedral geometry of carbon.^[36][37] Structural models prior to this work had been two-dimensional, and van 't Hoff and Le Bel theorized that the arrangement of groups around this tetrahedron could dictate the optical activity of the resulting compound through what became known as the Le Bel–van 't Hoff rule.

 

Marckwald's brucine-catalyzed enantioselective decarboxylation of 2-ethyl-2-methylmalonic acid, resulting in a slight excess of the levorotary form of the 2-methylbutyric acid product.^[38]

In 1894 Hermann Emil Fischer outlined the concept of asymmetric induction;^[39] in which he correctly ascribed selective the formation of D-glucose by plants to be due to the influence of optically active substances within chlorophyll. Fischer also successfully performed what would now be regarded as the first example of enantioselective synthesis, by enantioselectively elongating sugars via a process which would eventually become the Kiliani–Fischer synthesis.^[40]

 

Brucine, an alkaloid natural product related to strychnine, used successfully as an organocatalyst by Marckwald in 1904.^[38]

The first enantioselective chemical synthesis is most often attributed to Willy Marckwald, Universität zu Berlin, for a brucine-catalyzed enantioselective decarboxylation of 2-ethyl-2-methylmalonic acid reported in 1904.^[38][41] A slight excess of the levorotary form of the product of the reaction, 2-methylbutyric acid, was produced; as this product is also a natural product—e.g., as a side chain of lovastatin formed by its diketide synthase (LovF) during its biosynthesis^[42]—this result constitutes the first recorded total synthesis with enantioselectivity, as well other firsts (as Koskinen notes, first "example of asymmetric catalysis, enantiotopic selection, and organocatalysis").^[38] This observation is also of historical significance, as at the time enantioselective synthesis could only be understood in terms of vitalism. At the time many prominent chemists such as Jöns Jacob Berzelius argued that natural and artificial compounds were fundamentally different and that chirality was simply a manifestation of the 'vital force' which could only exist in natural compounds.^[43] Unlike Fischer, Marckwald had performed an enantioselective reaction upon an achiral, un-natural starting material, albeit with a chiral organocatalyst (as we now understand this chemistry).^[38][44][45]

Early work (1905–1965)

The development of enantioselective synthesis was initially slow, largely due to the limited range of techniques available for their separation and analysis. Diastereomers possess different physical properties, allowing separation by conventional means, however at the time enantiomers could only be separated by spontaneous resolution (where enantiomers separate upon crystallisation) or kinetic resolution (where one enantiomer is selectively destroyed). The only tool for analysing enantiomers was optical activity using a polarimeter, a method which provides no structural data.

It was not until the 1950s that major progress really began. Driven in part by chemists such as R. B. Woodward and Vladimir Prelog but also by the development of new techniques. The first of these was X-ray crystallography, which was used to determine the absolute configuration of an organic compound by Johannes Bijvoet in 1951.^[46] Chiral chromatography was introduced a year later by Dalgliesh, who used paper chromatography to separate chiral amino acids.^[47] Although Dalgliesh was not the first to observe such separations, he correctly attributed the separation of enantiomers to differential retention by the chiral cellulose. This was expanded upon in 1960, when Klem and Reed first reported the use of chirally-modified silica gel for chiral HPLC separation.^[48]

 

The two enantiomers of thalidomide:
Left: (S)-thalidomide
Right: (R)-thalidomide

Thalidomide

While it was known that the different enantiomers of a drug could have different activities, with significant early work being done by Arthur Robertson Cushny,^[49][50] this was not accounted for in early drug design and testing. However, following the thalidomide disaster the development and licensing of drugs changed dramatically.

First synthesized in 1953, thalidomide was widely prescribed for morning sickness from 1957 to 1962, but was soon found to be seriously teratogenic,^[51] eventually causing birth defects in more than 10,000 babies. The disaster prompted many countries to introduce tougher rules for the testing and licensing of drugs, such as the Kefauver-Harris Amendment (US) and Directive 65/65/EEC1 (EU).

Early research into the teratogenic mechanism, using mice, suggested that one enantiomer of thalidomide was teratogenic while the other possessed all the therapeutic activity. This theory was later shown to be incorrect and has now been superseded by a body of research.^[52] However it raised the importance of chirality in drug design, leading to increased research into enantioselective synthesis.

Modern age (since 1965)

The Cahn–Ingold–Prelog priority rules (often abbreviated as the CIP system) were first published in 1966; allowing enantiomers to be more easily and accurately described.^[53][54] The same year saw first successful enantiomeric separation by gas chromatography^[55] an important development as the technology was in common use at the time.

Metal-catalysed enantioselective synthesis was pioneered by William S. Knowles, Ryōji Noyori and K. Barry Sharpless; for which they would receive the 2001 Nobel Prize in Chemistry. Knowles and Noyori began with the development of asymmetric hydrogenation, which they developed independently in 1968. Knowles replaced the achiral triphenylphosphine ligands in Wilkinson's catalyst with chiral phosphine ligands. This experimental catalyst was employed in an asymmetric hydrogenation with a modest 15% enantiomeric excess. Knowles was also the first to apply enantioselective metal catalysis to industrial-scale synthesis; while working for the Monsanto Company he developed an enantioselective hydrogenation step for the production of L-DOPA, utilising the DIPAMP ligand.^[56][57][58]

Knowles: Asymmetric hydrogenation (1968)		Noyori: Enantioselective cyclopropanation (1968)

Noyori devised a copper complex using a chiral Schiff base ligand, which he used for the metal–carbenoid cyclopropanation of styrene.^[59] In common with Knowles' findings, Noyori's results for the enantiomeric excess for this first-generation ligand were disappointingly low: 6%. However continued research eventually led to the development of the Noyori asymmetric hydrogenation reaction.

 

The Sharpless oxyamination

Sharpless complemented these reduction reactions by developing a range of asymmetric oxidations (Sharpless epoxidation,^[60] Sharpless asymmetric dihydroxylation,^[61] Sharpless oxyamination^[62]) during the 1970s and 1980s. With the asymmetric oxyamination reaction, using osmium tetroxide, being the earliest.

During the same period, methods were developed to allow the analysis of chiral compounds by NMR; either using chiral derivatizing agents, such as Mosher's acid,^[63] or europium based shift reagents, of which Eu(DPM)₃ was the earliest.^[64]

Chiral auxiliaries were introduced by E.J. Corey in 1978^[65] and featured prominently in the work of Dieter Enders. Around the same time enantioselective organocatalysis was developed, with pioneering work including the Hajos–Parrish–Eder–Sauer–Wiechert reaction. Enzyme-catalyzed enantioselective reactions became more and more common during the 1980s,^[66] particularly in industry,^[67] with their applications including asymmetric ester hydrolysis with pig-liver esterase. The emerging technology of genetic engineering has allowed the tailoring of enzymes to specific processes, permitting an increased range of selective transformations. For example, in the asymmetric hydrogenation of statin precursors.^[23]

See also

• Aza-Baylis–Hillman reaction, for the use of a chiral ionic liquid in enantioselective synthesis
• Kelliphite, a chiral ligand widely used in asymmetric synthesis
• Spontaneous absolute asymmetric synthesis, the synthesis of chiral products from achiral precursors and without the use of optically active catalysts or auxiliaries. It is relevant to the discussion homochirality in nature.
• Tacticity, a property of polymers which originates from enantioselective synthesis
• Chiral analysis
• Enantioselective analysis

References

1. IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "asymmetric synthesis". doi:10.1351/goldbook.A00484
2. IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "stereoselective synthesis". doi:10.1351/goldbook.S05990
3. Gal, Joseph (2012). "The Discovery of Stereoselectivity at Biological Receptors: Arnaldo Piutti and the Taste of the Asparagine Enantiomers-History and Analysis on the 125th Anniversary". Chirality. 24 (12): 959–976. doi:10.1002/chir.22071. PMID 23034823.
4. Theodore J. Leitereg; Dante G. Guadagni; Jean Harris; Thomas R. Mon; Roy Teranishi (1971). "Chemical and sensory data supporting the difference between the odors of the enantiomeric carvones". J. Agric. Food Chem. 19 (4): 785–787. doi:10.1021/jf60176a035.
5. Lepola U, Wade A, Andersen HF (May 2004). "Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder". Int Clin Psychopharmacol. 19 (3): 149–55. doi:10.1097/00004850-200405000-00005. PMID 15107657. S2CID 36768144.
6. Hyttel, J.; Bøgesø, K. P.; Perregaard, J.; Sánchez, C. (1992). "The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer". Journal of Neural Transmission. 88 (2): 157–160. doi:10.1007/BF01244820. PMID 1632943. S2CID 20110906.
7. JAFFE, IA; ALTMAN, K; MERRYMAN, P (October 1964). "The Antipyridoxine Effect of Penicillamine in Man". The Journal of Clinical Investigation. 43 (10): 1869–73. doi:10.1172/JCI105060. PMC 289631. PMID 14236210.
8. Smith, Silas W. (July 2009). "Chiral Toxicology: It's the Same Thing...Only Different". Toxicological Sciences. 110 (1): 4–30. doi:10.1093/toxsci/kfp097. PMID 19414517.
9. IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "asymmetric induction". doi:10.1351/goldbook.A00483
10. Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. ISBN 978-0-19-850346-0.Page 1226
11. Bauer, Eike B. (2012). "Chiral-at-metal complexes and their catalytic applications in organic synthesis". Chemical Society Reviews. 41 (8): 3153–67. doi:10.1039/C2CS15234G. PMID 22306968.
12. Zhang, Lilu; Meggers, Eric (21 February 2017). "Steering Asymmetric Lewis Acid Catalysis Exclusively with Octahedral Metal-Centered Chirality". Accounts of Chemical Research. 50 (2): 320–330. doi:10.1021/acs.accounts.6b00586. ISSN 0001-4842. PMID 28128920.
13. Huang, Xiaoqiang; Meggers, Eric (19 March 2019). "Asymmetric Photocatalysis with Bis-cyclometalated Rhodium Complexes". Accounts of Chemical Research. 52 (3): 833–847. doi:10.1021/acs.accounts.9b00028. ISSN 0001-4842. PMID 30840435. S2CID 73503362.
14. N. Jacobsen, Eric; Pfaltz, Andreas; Yamamoto, Hisashi (1999). Comprehensive asymmetric catalysis 1-3. Berlin: Springer. ISBN 978-3-540-64337-1.
15. M. Heitbaum; F. Glorius; I. Escher (2006). "Asymmetric Heterogeneous Catalysis". Angewandte Chemie International Edition. 45 (29): 4732–4762. doi:10.1002/anie.200504212. PMID 16802397.
16. Asymmetric Catalysis on Industrial Scale, (Blaser, Schmidt), Wiley-VCH, 2004.
17. Roos, Gregory (2002). Compendium of chiral auxiliary applications. San Diego, CA: Acad. Press. ISBN 978-0-12-595344-3.
18. Glorius, F.; Gnas, Y. (2006). "Chiral Auxiliaries – Principles and Recent Applications". Synthesis. 2006 (12): 1899–1930. doi:10.1055/s-2006-942399.
19. Evans, D. A.; Helmchen, G.; Rüping, M. (2007). "Chiral Auxiliaries in Asymmetric Synthesis". In Christmann, M. (ed.). Asymmetric Synthesis – The Essentials. Wiley-VCH Verlag GmbH & Co. pp. 3–9. ISBN 978-3-527-31399-0.
20. IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "Biocatalysis". doi:10.1351/goldbook.B00652
21. Faber, Kurt (2011). Biotransformations in organic chemistry a textbook (6th rev. and corr. ed.). Berlin: Springer-Verlag. ISBN 978-3-642-17393-6.
22. Schmid, A.; Dordick, J. S.; Hauer, B.; Kiener, A.; Wubbolts, M.; Witholt, B. (2001). "Industrial biocatalysis today and tomorrow". Nature. 409 (6817): 258–268. Bibcode:2001Natur.409..258S. doi:10.1038/35051736. PMID 11196655. S2CID 4340563.
23. Müller, Michael (7 January 2005). "Chemoenzymatic Synthesis of Building Blocks for Statin Side Chains". Angewandte Chemie International Edition. 44 (3): 362–365. doi:10.1002/anie.200460852. PMID 15593081.
24. Berkessel, A.; Groeger, H. (2005). Asymmetric Organocatalysis. Weinheim: Wiley-VCH. ISBN 3-527-30517-3.
25. Special Issue: List, Benjamin (2007). "Organocatalysis". Chem. Rev. 107 (12): 5413–5883. doi:10.1021/cr078412e.
26. Gröger, Albrecht Berkessel; Harald (2005). Asymmetric organocatalysis – from biomimetic concepts to applications in asymmetric synthesis (1. ed., 2. reprint. ed.). Weinheim: Wiley-VCH. ISBN 3-527-30517-3.{{cite book}}: CS1 maint: multiple names: authors list (link)
27. Dalko, Peter I.; Moisan, Lionel (15 October 2001). "Enantioselective Organocatalysis". Angewandte Chemie International Edition. 40 (20): 3726–3748. doi:10.1002/1521-3773(20011015)40:20<3726::AID-ANIE3726>3.0.CO;2-D. PMID 11668532.
28. Notz, Wolfgang; Tanaka, Fujie; Barbas, Carlos F. (1 August 2004). "Enamine-Based Organocatalysis with Proline and Diamines: The Development of Direct Catalytic Asymmetric Aldol, Mannich, Michael, and Diels−Alder Reactions". Accounts of Chemical Research. 37 (8): 580–591. doi:10.1021/ar0300468. PMID 15311957.
29. Bertelsen, Søren; Jørgensen, Karl Anker (2009). "Organocatalysis—after the gold rush". Chemical Society Reviews. 38 (8): 2178–89. doi:10.1039/b903816g. PMID 19623342.
30. Allenmark, Stig G. (1988). Chromatographic enantioseparation : methods and applications. Chichester, West Sussex, England: E. Horwood. pp. 64–66. ISBN 0-85312-988-6.
31. Snyder, Lloyd R.; Kirkland, Joseph J.; Glajch, Joseph L. (28 February 1997). Practical HPLC Method Development. doi:10.1002/9781118592014. ISBN 978-1-118-59201-4.
32. Lakhtakia, A., ed. (1990). Selected Papers on Natural Optical Activity (SPIE Milestone Volume 15). SPIE.
33. Gal, Joseph (January 2011). "Louis Pasteur, language, and molecular chirality. I. Background and Dissymmetry". Chirality. 23 (1): 1–16. doi:10.1002/chir.20866. PMID 20589938.
34. Pasteur, L. (1848). Researches on the molecular asymmetry of natural organic products, English translation of French original, published by Alembic Club Reprints (Vol. 14, pp. 1–46) in 1905, facsimile reproduction by SPIE in a 1990 book.
35. Pedro Cintas (2007). "Tracing the Origins and Evolution of Chirality and Handedness in Chemical Language". Angewandte Chemie International Edition. 46 (22): 4016–4024. doi:10.1002/anie.200603714. PMID 17328087.
36. Le Bel, Joseph (1874). "Sur les relations qui existent entre les formules atomiques des corps organiques et le pouvoir rotatoire de leurs dissolutions" [On the relations which exist between the atomic formulas of organic compounds and the rotatory power of their solutions]. Bull. Soc. Chim. Fr. 22: 337–347.
37. van 't Hoff, J.H. (1874) "Sur les formules de structure dans l'espace" (On structural formulas in space), Archives Néerlandaises des Sciences Exactes et Naturelles, 9 : 445–454.
38. Koskinen, Ari M.P. (2013). Asymmetric synthesis of natural products (Second ed.). Hoboken, N.J.: Wiley. pp. 17, 28–29. ISBN 978-1-118-34733-1.
39. Fischer, Emil (1 October 1894). "Synthesen in der Zuckergruppe II". Berichte der Deutschen Chemischen Gesellschaft. 27 (3): 3189–3232. doi:10.1002/cber.189402703109.
40. Fischer, Emil; Hirschberger, Josef (1 January 1889). "Ueber Mannose. II". Berichte der Deutschen Chemischen Gesellschaft. 22 (1): 365–376. doi:10.1002/cber.18890220183.
41. Marckwald, W. (1904). "Ueber asymmetrische Synthese". Berichte der Deutschen Chemischen Gesellschaft. 37: 349–354. doi:10.1002/cber.19040370165.
42. Campbell, Chantel D.; Vederas, John C. (23 June 2010). "Biosynthesis of lovastatin and related metabolites formed by fungal iterative PKS enzymes". Biopolymers. 93 (9): 755–763. doi:10.1002/bip.21428. PMID 20577995.
43. Cornish-Bawden, Athel, ed. (1997), New Beer in an Old Bottle. Eduard Buchner and the Growth of Biochemical Knowledge, Universitat de València, pp. 72–73, ISBN 978-84-370-3328-0
44. Much of this early work was published in German, however contemporary English accounts can be found in the papers of Alexander McKenzie, with continuing analysis and commentary in modern reviews such as Koskinen (2012).
45. McKenzie, Alexander (1 January 1904). "CXXVII.Studies in asymmetric synthesis. I. Reduction of menthyl benzoylformate. II. Action of magnesium alkyl haloids on menthyl benzoylformate". J. Chem. Soc. Trans. 85: 1249–1262. doi:10.1039/CT9048501249.
46. Bijvoet, J. M.; Peerdeman, A. F.; van Bommel, A. J. (1951). "Determination of the Absolute Configuration of Optically Active Compounds by Means of X-Rays". Nature. 168 (4268): 271–272. Bibcode:1951Natur.168..271B. doi:10.1038/168271a0. S2CID 4264310.
47. Dalgliesh, C. E. (1952). "756. The optical resolution of aromatic amino-acids on paper chromatograms". Journal of the Chemical Society (Resumed): 3940. doi:10.1039/JR9520003940.
48. Klemm, L.H.; Reed, David (1960). "Optical resolution by molecular complexation chromatography". Journal of Chromatography A. 3: 364–368. doi:10.1016/S0021-9673(01)97011-6.
49. Cushny, AR (2 November 1903). "Atropine and the hyoscyamines-a study of the action of optical isomers". The Journal of Physiology. 30 (2): 176–94. doi:10.1113/jphysiol.1903.sp000988. PMC 1540678. PMID 16992694.
50. Cushny, AR; Peebles, AR (13 July 1905). "The action of optical isomers: II. Hyoscines". The Journal of Physiology. 32 (5–6): 501–10. doi:10.1113/jphysiol.1905.sp001097. PMC 1465734. PMID 16992790.
51. McBride, W. G. (1961). "Thalidomide and Congenital Abnormalities". The Lancet. 278 (7216): 1358. doi:10.1016/S0140-6736(61)90927-8.
52. Ito, Takumi; Ando, Hideki; Handa, Hiroshi (May 2011). "Teratogenic effects of thalidomide: molecular mechanisms". Cellular and Molecular Life Sciences. 68 (9): 1569–1579. doi:10.1007/s00018-010-0619-9. PMID 21207098. S2CID 12391084.
53. Robert Sidney Cahn; Christopher Kelk Ingold; Vladimir Prelog (1966). "Specification of Molecular Chirality". Angewandte Chemie International Edition. 5 (4): 385–415. doi:10.1002/anie.196603851.
54. Vladimir Prelog; Günter Helmchen (1982). "Basic Principles of the CIP-System and Proposals for a Revision". Angewandte Chemie International Edition. 21 (8): 567–583. doi:10.1002/anie.198205671.
55. Gil-Av, Emanuel; Feibush, Binyamin; Charles-Sigler, Rosita (1966). "Separation of enantiomers by gas liquid chromatography with an optically active stationary phase". Tetrahedron Letters. 7 (10): 1009–1015. doi:10.1016/S0040-4039(00)70231-0.
56. Vineyard, B. D.; Knowles, W. S.; Sabacky, M. J.; Bachman, G. L.; Weinkauff, D. J. (1977). "Asymmetric hydrogenation. Rhodium chiral bisphosphine catalyst". Journal of the American Chemical Society. 99 (18): 5946–5952. doi:10.1021/ja00460a018.
57. Knowles, William S. (2002). "Asymmetric Hydrogenations (Nobel Lecture)". Angewandte Chemie International Edition. 41 (12): 1999–2007. doi:10.1002/1521-3773(20020617)41:12<1998::AID-ANIE1998>3.0.CO;2-8. PMID 19746594.
58. Knowles, W. S. (March 1986). "Application of organometallic catalysis to the commercial production of L-DOPA". Journal of Chemical Education. 63 (3): 222. Bibcode:1986JChEd..63..222K. doi:10.1021/ed063p222.
59. H. Nozaki; H. Takaya; S. Moriuti; R. Noyori (1968). "Homogeneous catalysis in the decomposition of diazo compounds by copper chelates: Asymmetric carbenoid reactions". Tetrahedron. 24 (9): 3655–3669. doi:10.1016/S0040-4020(01)91998-2.
60. Katsuki, Tsutomu; Sharpless, K. Barry (1980). "The first practical method for asymmetric epoxidation". Journal of the American Chemical Society. 102 (18): 5974–5976. doi:10.1021/ja00538a077.
61. Jacobsen, Eric N.; Marko, Istvan.; Mungall, William S.; Schroeder, Georg.; Sharpless, K. Barry. (1988). "Asymmetric dihydroxylation via ligand-accelerated catalysis". Journal of the American Chemical Society. 110 (6): 1968–1970. doi:10.1021/ja00214a053.
62. Sharpless, K. Barry; Patrick, Donald W.; Truesdale, Larry K.; Biller, Scott A. (1975). "New reaction. Stereospecific vicinal oxyamination of olefins by alkyl imido osmium compounds". Journal of the American Chemical Society. 97 (8): 2305–2307. doi:10.1021/ja00841a071.
63. J. A. Dale, D. L. Dull and H. S. Mosher (1969). "α-Methoxy-α-trifluoromethylphenylacetic acid, a versatile reagent for the determination of enantiomeric composition of alcohols and amines". J. Org. Chem. 34 (9): 2543–2549. doi:10.1021/jo01261a013.
64. Hinckley, Conrad C. (1969). "Paramagnetic shifts in solutions of cholesterol and the dipyridine adduct of trisdipivalomethanatoeuropium(III). A shift reagent". Journal of the American Chemical Society. 91 (18): 5160–5162. doi:10.1021/ja01046a038. PMID 5798101.
65. Ensley, Harry E.; Parnell, Carol A.; Corey, Elias J. (1978). "Convenient synthesis of a highly efficient and recyclable chiral director for asymmetric induction". The Journal of Organic Chemistry. 43 (8): 1610–1612. doi:10.1021/jo00402a037.
66. Sariaslani, F.Sima; Rosazza, John P.N. (1984). "Biocatalysis in natural products chemistry". Enzyme and Microbial Technology. 6 (6): 242–253. doi:10.1016/0141-0229(84)90125-X.
67. Wandrey, Christian; Liese, Andreas; Kihumbu, David (2000). "Industrial Biocatalysis: Past, Present, and Future". Organic Process Research & Development. 4 (4): 286–290. doi:10.1021/op990101l.